key: cord-0757169-hcp4t67x
authors: Collier, Dami A.; Assennato, Sonny M.; Warne, Ben; Sithole, Nyarie; Sharrocks, Katherine; Ritchie, Allyson; Ravji, Pooja; Routledge, Matthew; Sparkes, Dominic; Skittrall, Jordan; Smielewska, Anna; Ramsey, Isobel; Goel, Neha; Curran, Martin; Enoch, David; Tassell, Rhys; Lineham, Michelle; Vaghela, Devan; Leong, Clare; Mok, Hoi Ping; Bradley, John; Smith, Kenneth GC.; Mendoza, Vivienne; Demiris, Nikos; Besser, Martin; Dougan, Gordon; Lehner, Paul J.; Siedner, Mark J.; Zhang, Hongyi; Waddington, Claire S.; Lee, Helen; Gupta, Ravindra K.
title: Point of care nucleic acid testing for SARS-CoV-2 in hospitalised patients: a clinical validation trial and implementation study.
date: 2020-07-15
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2020.100062
sha: 7eb5c45540a7001d9c1e944fbaa1ffdbaddc3b2b
doc_id: 757169
cord_uid: hcp4t67x

Summary There is urgent need for rapid SARS-CoV-2 testing in hospital to limit nosocomial spread. We report an evaluation of point of care (POC) nucleic acid amplification testing (NAAT) in 149 participants with parallel combined nasal/throat swabbing for POC versus standard lab RT-PCR testing. Median time to result is 2.6 (IQR 2.3 to 4.8) versus 26.4 hours (IQR 21.4 to 31.4, p<0.001) with 32 (21.5%) positive and 117 (78.5%) negative. Cohen's kappa correlation between tests is 0.96 (95%CI 0.91, 1.00). When comparing nearly 1000 tests pre- and post- implementation, median time to definitive bed placement from admission is 23.4 (8.6-41.9) versus 17.1 hours (9.0-28.8), p=0.02. Mean length of stay on COVID-19 ‘holding’ wards is 58.5 versus 29.9 hours (p<0.001). POC testing increases isolation room availability, avoids bed closures, allows discharge to care homes and expedites access to hospital procedures. POC testing could mitigate the impact of COVID-19 on hospital systems.

As of 22 nd of June 2020, 9.0 million people have been infected with SARS-CoV-2 with over 90 469,939 deaths and 40,000 deaths in the UK attributed to COVID-19 1 . Current clinical 91 testing for acute SARS-CoV-2 infection and infection risk relies on nucleic acid detection 92 using reverse transcription polymerase chain reaction (RT-PCR) on nose/throat swabs 2,3 . 93

Antibodies to SARS-CoV-2 are detectable in only 50% by day 5-7 4 and are therefore not 94 suitable as a test for early infection, although they are useful in the second phase of illness 95 when virus detection wanes in upper respiratory tract samples 3,5 . Antigen tests for COVID-19 96 diagnosis have performed poorly to date and therefore nucleic acid detection remains the test 97 of choice. Nucleic acid testing usually requires central laboratory testing with concomitant 98 delays, and turnaround times are usually in excess of 24 hours, and often days 6 . Due to 99 diverse presentations of COVID-19 7 , lack of a timely diagnosis can have serious 100 consequences, including deadly nosocomial outbreaks 8 . 101 102 Screening hospital admissions rapidly is therefore critical in order to manage patient flow and 103 limit potential for nosocomial transmission 9,10 . In the absence of a reliable POC test, hospitals 104 have resorted to creating bespoke care pathways in order to use isolation rooms most 105 effectively for vulnerable patients 11 . Finally, given care home outbreaks, there is also urgent 106 need to rapidly demonstrate COVID-19 status on discharge planning. This need for rapid and 107 safe patient movement is likely to increase sharply in late 2020 when norovirus and influenza 108 (with or without SARS-CoV-2 12 ) will likely compound pressure on hospitals and isolation 109 capacity in particular. Such an approach would also relieve pressure on hospital virology 110 laboratories so they can resume routine testing. 111 112 A number of near patient tests have been described. Some have not performed well 13 , and 113 none have undergone testing under rigorous clinical trial conditions with 'real world' data on 114 impact on patient managment [14] [15] [16] [17] [18] . Thorough, prospective evaluation for a high consequence 115 pathogen such as SARS-CoV-2 is particularly important given risks related to false positives 116 or negatives in the hospital setting. 117 118 SAMBA (simple amplification based assay), an isothermal amplification based platform, has 119 been extensively field tested for HIV diagnostic applications in low resource settings 19, 20 , and 120 has been adapted for use in SARS-CoV-2 with successful pre-clinical testing using synthetic 121 standards and stored positive and negative clinical samples 21 . Here we present a prospective 122 clinical validation trial comparing SAMBA II SARS-CoV-2 performance against the 123 standard lab RT-PCR test in suspected COVID-19 cases presenting to hospital, followed by 124 analysis of POC implementation in hospital. 125 126

Of 178 screened patients, 149 met eligibility criteria for inclusion in the clinical trial ( Figure  129 1). Mean age was 62.7 years and 47% were male. 32/149 (21.6%) tested positive by the 130 standard lab RT-PCR test. Mean temperature and respiratory rate were higher in the standard 131 lab RT-PCR positive group (Table 1) . Median duration of symptoms was 3 (IQR 1.75-10.5) 132 and 4 (IQR 2-13) days in standard lab RT-PCR positive and negative participants 133 respectively. There were seven discrepant results between the POC and laboratory assays 134 (7/149) after initial testing. Discrepancy analysis concluded that there was one false negative 135 by the POC test, likely related to sampling variation, and no false positives (supplementary 136 no beneficial impact was found, 7 of these had a previous recent test result of which 2 were 204 known positive, and a SAMBA positive result had no further impact. In 4 instances, the 205 patient had been moved prior to the result returning as clinical suspicion of COVID-19 was 206 high leading to triage prior to the result being known, in 8, there was no documented 207 indication and in the rest SAMBA II SARS-CoV-2 testing did not alter management. 208 209 210

Next we compared clinical outcomes in the 10 days prior to and following SAMBA II SARS-211

CoV-2 introduction. Duplicate tests in the same admission episode were excluded. We Table 3 ). Time from sample to test result fell dramatically [35.9 hours (23.8-48.9) to 219 3.8 hours (2.7-6.0), p<0.0001, Figure 4A shows Kaplan-Meier analysis]. Time to definitive 220 ward move from admission also decreased significantly after SAMBA II SARS-CoV-2 221 introduction [23.4 hours (8.6-41.9) to 17.1 hours (9.0-28.8), p=0.02, Figure 4B shows 222

Kaplan-Meier analysis]. The Cox proportional hazards regression model showed that even 223 after mutually adjusting for age, gender, quick sequential organ failure assessment score 224 (qSOFA), national early warning score 2 (NEWS2), and Charlson Comorbidity Index (CCI), 225 SAMBA II SARS-CoV-2 test was independently associated with the shorter time to 226 definitive bed placement from admission [HR 1.25 (95% CI 1.02-1.53), p=0.03]. Other 227 significant associations were younger age and NEWS2 medium risk score. (Supp Table 4 ). 228

Finally, mean length of stay on a COVID-19 result wait/holding ward decreased from 58.5 229 hours to 29.9 hours (p<0.001) compared to the 10 days prior to implementation. 230 231 Discussion 232

Here we report the impact of rapid POC molecular SARS-CoV-2 testing for diagnosis of 233 test has a turnaround time of around 3 hours post-RNA extraction, the median turnaround 247 times of >24 hours in our study reflects the logistical challenges of performing these tests at 248 the peak of the epidemic in our hospital. Specimens were handled in BSL 3 laboratory and 249 batch run, which created a significant delay. This aspect of delay was overcome by the 250 SAMBA II platform which uses an inactivation buffer, thereby avoiding the requirement for 251 viral transport media and BSL2/3 facilities. 252 253 Patient placement during the COVID-19 pandemic has been a significant challenge and has 254 significantly impacted the ability to maintain patient flow and safety in hospital. The trial 255 data on SAMBA II raised the prospect of addressing these problems. Our hospital switched 256 from standard lab RT-PCR testing to SAMBA II for in-hospital testing immediately 257 following the end of the validation study, providing an opportunity to prospectively evaluate 258 almost 1000 tests performed over ten consecutive days. Most tests were performed on new 259 admissions to hospital and replicated the significant reduction in test turnaround time 260 observed in the clinical validation trial. 261 262 POC was also used to investigate newly symptomatic patients in hospital to rationalise our 263 limited isolation rooms, and also to rapidly identify new COVID-19 cases with appropriate 264 infection control and prevention of nosocomial outbreaks 10 . Inappropriate isolation is a large 265 drain on staff and resources due to the need for repeated deep cleaning, additional PPE 266 utilisation and the distress and risk to patients from repeated bed moves 24 . As expected, we 267 observed a significant increase in the availability of isolation/ single occupancy rooms following POC introduction, and also patients testing negative were able to be placed in low 269 risk areas of the hospital and have interventions/procedures expedited. 270

We found that 11 ward closures were prevented in the ten-day post implementation phase by 272 having negative tests in symptomatic hospital patients. Closed surgical bays in particular can 273 result in cancellations of operations, as well as significant financial losses to hospitals. 274

Following this analysis, hospital guidelines will be adapted to recommend waiting for 275 SAMBA test results before moving patients into isolation or closing bays. 276 277 When then performed formal implementation impact analysis using ten day windows either 278 side of May 2 nd 2020, we found that time to definitive ward move from admission decreased 279 significantly after SAMBA II SARS-CoV-2 introduction, and length of stay on the main 280 holding ward where test results were awaited also fell significantly, consistent with more 281 rapid and accurate patient movement. 282 283 Although we did not conduct a cost benefit analysis in this study, the utilisation of POCT in 284 acute settings for other respiratory viruses has been shown to be cost effective 25 . Given the 285 morbidity and mortality associated with COVID-19, as well as the disruption that this 286 pandemic has placed on healthcare provision, we anticipate that SAMBA II SARS-CoV-2 287 implementation is also likely to be a cost-effective intervention through reductions in delayed 288 discharge, nosocomial transmission and unnecessary use of personal protective equipment. 289

Formal economic analyses of POCT implementation in pandemic settings are required. 290 291 SAMBA II SARS-CoV-2 test is being implemented in a very limited number of hospitals, but 292 there is urgent need for POC capacity in care homes, prisons and possibly other 293 establishments. A POC platform also has the potential to reduce disparities between 294 secondary and tertiary medical centres that have specialised virology laboratories, and ensure 295 equitable access to timely SARS-CoV-2 testing results. SAMBA II machines are already in 296 use in Uganda, Zimbabwe and Kenya for HIV testing and monitoring. If scale up can be 297 achieved in those settings, POC testing could be vital for controlling COVID-19 in sub-298

Saharan Africa 8 and our data will inform their optimal use 26 . 299 300 Finally, based on the data presented, we predict that implementation of POC testing for 301 SARS-CoV-2 could have a critical impact on hospital management of suspected COVID-19 302 cases, particularly in the context of influenza and norovirus seasons. 303

Limitations 305

The clinical test validation component was limited by the fact that the same swab could not 306 be tested on the two platforms being compared. This raised an issue of two separate samples 307 being tested on the two assays. Nonetheless, we identified only two cases where the sampling 308 may have explained discrepant results. In addition, the SAMBA II SARS-CoV-2 test is not 309 able to give viral load or cycle threshold values for more nuanced analysis. The 310 implementation phase took place 6 weeks into the UK lockdown, at a time when the rate of 311 new infections had reduced substantially across the country. Nonetheless, the study 312 highlights the importance of rapid test results in the COVID-19 era, regardless of the 313 outcome of the test results. It should also be borne in mind that nucleic acid tests on 314 nose/throat swabs can be negative in COVID-19 disease, particularly when presentation to 315 hospital is beyond 7 days 27 . However, for general hospital infection control purposes, 316 nose/throat nucleic acid detection is seen to be appropriate for infection control and triaging 317 purposes. Finally, use of a proprietary inactivation buffer may limit the generalizability of the 318 platform, particularly since supply shortages are a major problem for COVID-19 diagnostic 319 assays. The study was conducted in two phases; a clinical validation phase followed by an 477 implementation phase. Following the completion of the COVIDx validation study (May 1 st 2020) and demonstration 518 of performance equivalent to the reference standard test, the hospital switched from standard 519 lab RT-PCR testing to use of SAMBA II for in-hospital testing due to its shorter turnaround 520 time. There were no changes in the testing criteria over the implementation study. Twenty 521 SAMBA II machines were operationalised by the CUH POC testing team, each machine 522 capable of performing around 10-15 tests per day. To evaluate the real-world impact of 523 SAMBA on clinical care, we retrospectively gathered data on clinically relevant endpoints 524 from electronic patient records over a ten-day period before and after introduction of the 525 SAMBA test for all patients who underwent COVID-19 testing. 526 527 All patients who underwent COVID-19 testing in a 10 day period before and after 528 introduction of the SAMBA II SARS-CoV-2 test were included. Participants were identified 529 from testing reports from the EPIC electronic hospital records system. Clinical and hospital 530 activity data were obtained from the same source. The determination of whether the SAMBA 531 II SARS-CoV-2 test was of benefit or not was made by a clinician who reviewed each 532 which uses nucleic acid sequence based amplification to detect SARS-CoV-2 RNA from 545 throat and nose swab specimens collected by dry sterile swab and inactivated in a proprietary 546 inactivation buffer prior to analyses. This obviates the need for a BSL3 laboratory for 547 specimen handling or viral extraction. The SAMBA II SARS-CoV-2 targets 2 genes-Orf1 548 and the E genes. The limit of detection (LoD) of the SAMBA II SARS-CoV-2 Test is 250 549 copies/ml 21 . The SAMBA II instrument system consists of the SAMBA II Assay Module 550 (P/N I19-0006-AM) and the SAMBA II Tablet Module (P/N I19-0006-TM). The assay 551 module sits on a bench top at room temperature and has an approximate size of 552 20cmx20cmx20cm. The SAMBA II SARS-CoV-2 test contains all materials required for 553 extraction of viral nucleic acid from the specimen, amplification of the nucleic acid target and 554 the detection of the amplification products. All cartridges required to test one sample using 555 SAMBA II SARS-CoV-2 test are packaged in a One Test Set bag. The assay module is able 556 to process one sample at a time and takes 90 minutes to run. One assay module is able to 557 perform 10-15 tests in a 24-hour period. 558 559 There is currently no gold standard for the diagnosis of COVID-19. In lieu of a gold standard 560 the reference standard used for this study is an in-house RT-PCR test developed in the public 561 health England (PHE) laboratory at CUH with a LOD of 320 copies/ml. This test was 562 performed on the Qiagen Roto gene platform which gives a result in 3 hours and able to 563 perform 100 samples at a time. Specimens were handled in at BSL 3 laboratory and batch 564 run, both of which contributed to increased TAT (test turnaround time). 565 566 Indeterminate SAMBA II SARS-CoV-2 tests occurred if the positive control line was absent 567 on the test strip and were repeated with a 1:2 dilution of sample to inactivation buffer 568 according to manufacturer standard operating procedures until a valid result was obtained. 569

For lab RT-PCR, a dilution of the MS2 bacteriophage was added to all samples prior to the 570 extraction step to act as an internal/inhibition control. In the result of internal control failure, 571 the result was classed as "invalid". The results of the SAMBA II SARS-CoV-2 was not 572 known to the assessors of the standard lab RT-PCR. 573 574 Data Collection 575 576 Demographic and clinical data were obtained at presentation from the hospital's electronic 577 patient records (EPIC) and entered into anonymised case report forms on the MACRO 578 electronic database. Biological specimens from a combined nose and throat swab were 579 collected and stored by research nurses. Results were not made available to clinical teams 580 during the study. The primary outcome measures were time to result, concordance with the 581 standard lab RT-PCR test and sensitivity/specificity of the SAMBA II SARS-CoV-2 test. 582 583 Ethical approval 584 585 The protocol was approved by the East of England -Essex Research Ethics Committee. HRA 586 and Health and Care Research Wales (HCRW) approval was received. Verbal informed 587 consent was obtained from all participants or in the case of participants without capacity, 588 from a consultant nominee who was involved in their clinical care but independent from the 589 research team. The implementation study was registered as a service evaluation with 590 We assumed a target sensitivity of 0.95 and disease prevalence of 15%. Using a 5% 602 significance level and allowing for an error of 10% gave a required sample size of 122. 603

Participants with missing SAMBA II SARS-CoV-2 or standard lab RT-PCR tests result were 604 excluded from the analyses. Descriptive analyses of clinical and demographic data are 605 presented as median and interquartile range (IQR) when continuous and as frequency and 606 proportion (%) when categorical. The difference in continuous and categorical data were 607 tested using Wilcoxon rank sum and Chi-square test respectively. Agreement between the 608 two tests was assessed using Cohen's kappa, a correlation-like measure which accounts for 609 agreement by chance alone, in which case κ = 0, while κ = 1 and κ = -1 correspond to perfect 610 agreement and completely discordant pairs respectively. Sensitivity and specificity of 611 SAMBA II SARS-CoV-2 test were presented with exact Clopper-Pearson 95% confidence 612 intervals due to estimates being near 1. Kaplan Meier survival analysis was used to compare 613 time to result for the two tests, with log rank testing. Analysis was done using R and STATA 614 version 13. 615

The Laboratory Diagnosis of 657 COVID-19 Infection: Current Issues and Challenges

Viral load of SARS-CoV-2 in clinical 659 samples

Antibody responses to SARS-CoV-2 in patients 661 with COVID-19

Virological assessment of hospitalized 663 patients with COVID-2019. Nature 2020. 664 6. Journal HS. Trusts concerned over long waits for covid-19 test results

Clinical features 668 of covid-19

Report into a nosocomial outbreak of 670 coronavirus disease 2019 (COVID-19) at Netcare St. Augustine's Hospital

Intensive care management of coronavirus disease 672 2019 (COVID-19): challenges and recommendations

Screening of healthcare workers for SARS-CoV-674 2 highlights the role of asymptomatic carriage in COVID-19 transmission

A Novel Cohorting and Isolation 676 Strategy for Suspected COVID-19 Cases during a Pandemic

Comparative study of four SARS-CoV-2 680

Nucleic Acid Amplification Test (NAAT) platforms 1 demonstrates that ID NOW 681 performance is impaired substantially by patient and specimen type

Sample-To-Answer Platforms for the Detection of SARS-CoV-2

Comparison of Commercially Available and Laboratory Developed Assays for in vitro 688 Detection of SARS-CoV-2 in Clinical Laboratories

Now to Roche cobas for the Rapid Detection of SARS-CoV-2

Diasorin Simplexa, and CDC FDA EUA methods for the 694 detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed 695 with COVID-19

Evaluation of the QIAstat-Dx Respiratory 697 SARS-CoV-2 Panel, the first rapid multiplex PCR commercial assay for SARS-CoV-2 698 detection

Performance of the SAMBA I and II 700 HIV-1 Semi-Q Tests for viral load monitoring at the point-of-care

Multicountry Validation of 703 SAMBA -A Novel Molecular Point-of-Care Test for HIV-1 Detection in Resource-Limited 704

Performance evaluation of the point-of-706 care SAMBA II SARS-CoV-2 Test for detection of SARS-CoV-2 MedRxiv 2020

Mortality and pulmonary complications in patients undergoing 708 surgery with perioperative SARS-CoV-2 infection: an international cohort study

Features of 20 133 UK patients in 711 hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: 712 prospective observational cohort study

Bed Moves, Ward Environment, Staff 714 Perspectives and Falls for Older People with High Falls Risk in an Acute Hospital: A Mixed 715 Methods Study

Diagnostic accuracy and cost analysis of the 717

Alere i Influenza A&B near-patient test using throat swabs

Clinical infectious diseases : an official publication of the 721 Infectious Diseases Society of America 2020. 722 28. Public Health England. Total UK COVID-19 Cases Update

report testing and implementation of an accurate SARS-CoV-2 point of care nucleic acid amplification test that leads to faster time to definitive bed placement from the ER, release of isolation rooms, avoidance of bed closures

Highlights • Point of care (POC) test highly sensitive and specific against RT-PCR • Time to result 2.6hrs for POC v 26

CoV-2 POC test reduces median time-to-bed placement by approximately six hours • SARS-CoV-2 POC improves indices of hospital functioning and patient care